Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

GNBT - Generex Biotechnology - Deel 3

703 Posts
Pagina: «« 1 2 3 4 5 6 ... 36 »» | Laatste | Omlaag ↓
  3. [verwijderd] 6 maart 2009 18:16

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    durfinvest schreef:

    ~~ 0.12 USD ~~ .............. en nergens meer te zien Meneer Skyspam1 met z,n grote mond hehe...typisch zulke mensen.
    GNBT 0.11 USD -0.01(-8.33%)
  4. [verwijderd] 6 maart 2009 23:41

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    durfinvest schreef:

    [quote=durfinvest]
    ~~ 0.12 USD ~~ .............. en nergens meer te zien Meneer Skyspam1 met z,n grote mond hehe...typisch zulke mensen.
    [/quote]GNBT 0.11 USD -0.01(-8.33%)
    ~~ 0,10 ~~
  6. [verwijderd] 9 maart 2009 19:32

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    durfinvest schreef:

    GNBT 0.08 USD -0.02(-20.00%) ... en Skyspam met z,n grote mond nergens meer te zien ?
    Ernstig zieke en verslaafde meneer Durfinvest: stop toch met die onzin.
  7. [verwijderd] 10 maart 2009 08:10

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    crackedtooth schreef:

    aantal leuke ritjes hier gehad van 0,30 naar 0,37
    Ja altijd alles achteraf en nu de koers op 0,08 staat hehehe, geef ook eens 1 keer in uw leven 1 STIJG tip VAN TE VOREN graag, kan ik ook eens mee doen, altijd hetzelfde met die gastjes...alles achteraf , zo kan iedereen het.
  8. [verwijderd] 10 maart 2009 08:23

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Het is schandalig dat GNBT zo'n slecht beleid heeft gevoerd . Totaal geen info naar de aandeelhouders of er iets aan de hand zou kunnen zijn . Het lijkt wel een zeer arrogante houding .

    Ook houden ze op hun site de press release zeer slecht bij .

    Ik keek zojuist en zie dat er 2 nieuwe (goede persberichten op zijn gezet , maar wel van 2 en 3 maart . Ik zal ze in de volgende berichten zetten .

    Het is onbegrijpelijk dat de koers zo ver heeft kunnen dalen zonder ingrijpen .

    Het aandeel is volledig kapot geshort .

    Als het goed is komt het bedrijf vandaag of morgen met een update . Misschien daarna wel sterk herstel . Erg veel kan er nu in ieder geval niet meer af op 0,08 .
  9. [verwijderd] 10 maart 2009 08:24

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Press Release

    Generex Oral-lyn(TM) to be presented at International Conference on Advances in Diabetes and Insulin

    March 02, 2009

    Conference to be held in Mumbai, India

    WORCESTER, Mass., Mar 02, 2009 (BUSINESS WIRE) -- Generex Biotechnology Corporation (NasdaqCM:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that Professor Paolo Pozzilli of the Department of Endocrinology & Diabetes at University Campus Bio-Medico, Rome, Italy, will make a podium presentation in respect of Generex Oral-lyn, the Company's proprietary oral insulin spray product, at the International Conference on Advances in Diabetes and Insulin Therapy to be held in Mumbai, India, March 19 - 22, 2009 (www.adit2009.org).

    Professor Pozzilli will present his paper entitled Buccal Spray Insulin for Treatment of Diabetes. The paper concludes that Generex Oral-lyn is able to control plasma glucose as well as fast-acting injectable insulin analogs (lispro, aspart, glulisine) and can be used to control post-prandial hyperglycaemia (impaired glucose tolerance).

    "We are pleased with Professor Pozzilli's opportunity to present Generex Oral-lyn to this international scientific conference," said Anna Gluskin, Generex's President and Chief Executive Officer, "particularly as the product rollout has been initiated in India and our global Phase 3 trial continues."

    The goals of the conference are education, the creation of a platform for an exchange of opinions and in-depth discussion on insulin therapy, the stimulation of research, and the implementation of cutting-edge technologies and therapies in treating diabetes, all through plenary lectures, poster sessions and workshops.

    About Generex Biotechnology Corporation

    Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in India and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. For more information, visit the Generex website at www.generex.com.

    Safe Harbor Statement

    This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

    SOURCE: Generex Biotechnology Corporation

    For Generex:
    American Capital Ventures, Inc.
    Howard Gostfrand, 1-877-918-0774


  10. [verwijderd] 10 maart 2009 08:25

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Press Release

    Generex Biotechnology Announces Treatment of First Patient With Its Novel Immunotherapeutic Vaccine

    March 03, 2009

    WORCESTER, Mass., Mar 3, 2009 (GlobeNewswire via COMTEX News Network) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) announced today that the first patient has received its immunotherapeutic AE37 vaccine as part of a new combination therapy approach for breast and ovarian cancer patients. This vaccine therapy is designed to activate immune cells that can detect and destroy cancer cells. AE37 is being developed by the Company's wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The new Phase I clinical trial, being performed at the Mary Crowley Cancer Research Centers ("Mary Crowley") in Dallas and the Brooke Army Medical Center ("BAMC") in San Antonio, will assess safety and immunological response in patients with either breast and/ or ovarian cancer. Patients in the study will be clinically cancer free, having completed primary standard of care breast and/or ovarian therapies.

    The Generex vaccine being used in this study, AE37, is designed to increase immune response. This design specifically increases the ability of CD4+ T helper cells to recognize HER-2/neu expressing cancer cells in immunized patients, which should prompt the immune system to mount a robust anti-cancer response. The cancers of all patients in these trials express some level of HER-2/neu. An advantage of using this type of active immunotherapy, as opposed to passive immunotherapy such as treatment with Herceptin, is that activated immune cells can detect and destroy cancer cells expressing much lower levels of HER-2/neu than is needed for recognition by Herceptin.

    The Company's AE37 vaccine is currently the subject of a Phase II investigation in patients with breast cancer as well as a Phase I trial in prostate cancer patients. The Phase II study is being conducted by Dr. George Peoples of BAMC while the Phase I prostate cancer study is being conducted by Drs. Karagiannis and Baxevanis at the Euroclinic in Athens, Greece. The results of a Phase I study of AE37 in breast cancer patients were recently published in the Journal of Clinical Oncology (vol. 26, pages 3426-3433, 2008). The immunotherapeutic vaccine was found to be safe, well-tolerated, and produced the desired immunological response.

    In this new trial, AE37 will be paired with a second HER-2/neu-derived peptide designed to stimulate a different portion of the immune system. The trial results will determine both safety and immunological response. Mary Crowley investigators Dr. John Nemunaitis and Dr. Neil Senzer helped design the clinical study as part of a collaboration between Dr. George Peoples at BAMC, Mary Crowley and Antigen Express.

    "We are very excited to be initiating this new Phase I trial," commented Dr. Eric von Hofe, President of Antigen Express. "The trial represents a significant expansion in the clinical development of the AE37 immunotherapeutic cancer vaccine."

    About Generex Biotechnology Corporation

    Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in India and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

    The Generex Biotechnology Corp. logo is available at www.globenewswire.com/newsroom/prs/?p...

    Safe Harbor Statement

    This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

    This news release was distributed by GlobeNewswire, www.globenewswire.com

    SOURCE: Generex Biotechnology Corp.

    American
    Capital Ventures, Inc.
    Howard Gostfrand
    1-877-918-0774


  11. [verwijderd] 10 maart 2009 08:27

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    En deze stond er ook nog niet op !

    Note to A-Rod: BaBOOM!(TM) is Legal and We'll Give It to You for Free

    February 20, 2009

    Generex's BaBOOM!(TM) Energy Spray provides safe, legal "kick"

    WORCESTER, Mass., Feb 20, 2009 (BUSINESS WIRE) -- While the public disgrace of New York Yankee Alex Rodriguez has shocked the sports world, the alleged use of performance enhancing drugs hardly makes A-Rod unique among his peers - do Roger Clemens, Jose Canseco, Mark McGwire, or Sammy Sosa ring a bell?

    While increased strength, bulk, and speed can raise an athlete's performance to elite stardom level, illegal steroids are clearly not the answer. And while time in the weight room may guarantee 40 home runs, using BaBoom!(TM) could help A-Rod achieve power numbers of "Ruthian" dimensions.

    In fact, we are so confident that A-Rod will get a lift from BaBoom!(TM), we are willing to offer him a year's supply of BaBoom!(TM) for free, as long as he steers clear of any illegal performance enhancing drugs.

    Generex today sent a letter with the free BaBOOM!(TM) offer to Alex Rodriguez, copying Major League Baseball Commissioner Bud Selig, Players Association COO and Health Policy Advisory Council member Gene Orza, and Yankee owners George, Hank and Hal Steinbrenner.

    Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, reminds A-Rod and all those looking for a performance-enhancing edge that Generex's BaBOOM!(TM) Energy Spray is available - legally - at convenience stores and drug stores and online at www.baboomenergyspray.com.

    "There's no doubt that the youth in our community are influenced by the behavior of their role models, especially teenagers who are looking for a competitive edge," said Bill Abajian, senior executive advisor for global strategic alliances & business development at Generex. "But there's no easy way to achieve greatness without hard work, and BaBOOM!(TM) is a trueenergy supplement that supports those efforts."

    BaBOOM!(TM) Energy Spray is a fruit-flavored oral spray designed to quickly raise energy levels through its innovative blend of glucose, caffeine, taurine, vitamin B3 and vitamin B6. The unique delivery system promotes rapid absorption into the body, for fast results at less than 5 calories per serving. BaBOOM!(TM) is a portable, easy to use and convenient way to help sustain energy levels while playing sports, working, studying or traveling.

    About Generex Biotechnology Corporation

    Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in India and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. For more information, visit the Generex website at www.generex.com.

    SOURCE: Generex Biotechnology Corporation

    Avalanche Strategic Communications
    Angelene Taccini
    201-488-0049 office
    201-916-0067 cell
    angelene@avalanchepr.com
    or
    Generex Biotechnology
    Bill Abajian, 973-568-1617
    abajian@generex.com


  13. [verwijderd] 10 maart 2009 15:45

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Dit is super nieuws .

    Alleen schandalig dat ze het aandeel tot bijna het 0 punt hebben laten dalen .

    De zittende aandeelhouder is/wordt behoorlijk getest.

    De nu instappende aandeelhouder heeft mazzel met zo'n absurt lage koers .

  14. [verwijderd] 10 maart 2009 15:47

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Generex Biotechnology Announces Successful Phase III Study Data for Generex Oral-lyn(tm)
    Tuesday March 10, 2009, 9:30 am EDT
    Buzz up! Print Related:Generex Biotechnology Corp.
    WORCESTER, Mass., March 10, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News) (http://www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced positive results following the review of the Phase III data for the Company's flagship product, Generex Oral-lyn, a proprietary oral insulin spray product designed to replace prandial injections of insulin.

    Related Quotes
    Symbol Price Change
    GNBT 0.15 +0.07


    {"s" : "gnbt","k" : "c10,l10,p20,t10","o" : "","j" : ""} Generex, together with the Company's independent third party statistical and data monitoring consultants, will continue to monitor the ongoing pivotal Phase III Generex Oral-lyn study according to protocol and national/international ICH-GCPs. To date, more than 300 subjects have been enrolled in the study (with 60 subjects having achieved the requisite six-month treatment milestone) and the product's non-inferiority to injectable meal-time (prandial) insulin appears to be maintained. If the current positive trend is maintained, then a large reduction of required enrollment will suffice for formal verification of the non-inferiority hypothesis.

    The current data also demonstrates that no significant Generex Oral-lyn drug-related ``Adverse Events'' or ``Serious Adverse Events'' have been reported, which also supports the current initiatives of the study.

    ``The current data and trends represent a critical milestone for the Company,'' said Anna Gluskin, Generex's President and Chief Executive Officer. ``These results are consistent with the results of our previous studies. This will allow us greater flexibility in our strategies for filing submissions with regulatory authorities in major global markets and other jurisdictions where applications are already in progress.''

    The Company believes that Generex Oral-lyn will offer a safe, simple, fast, effective and pain-free alternative to prandial insulin injections which will improve patient compliance with therapeutic regimes thereby delaying the progress of diabetes and the onset of its myriad complications.

    About Generex Biotechnology Corporation

    Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in India and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. For more information, visit the Generex website at www.generex.com.

    The Generex Biotechnology Corp. logo is available at www.globenewswire.com/newsroom/prs/?p...

    Safe Harbor Statement

    This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain ``forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as ``expects,'' ``plans,'' ``intends,'' ``believes,'' ``will,'' ``estimates,'' ``forecasts,'' ``projects,'' or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any ``phase'' of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

    Contact:
    American Capital Ventures, Inc.
    Howard Gostfrand
    1-877-918-0774
  19. [verwijderd] 10 maart 2009 17:22

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ik ben nog niet (helemaal ) blij

    Het aandeel stond 1 maand geleden nog 0,31
    en 3 maanden geleden nog 0,50
    en 1 jaar geleden nog 1$
    en 3 jaar geleden nog 4 $

    dus stelt het herstel nog geen fluit voor ,

    maar beter iets dan niets

703 Posts
Pagina: «« 1 2 3 4 5 6 ... 36 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.853
AB InBev 2 5.309
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.580 47.115
ABO-Group 1 19
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 9.041
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 32
Adomos 1 126
AdUX 2 457
Adyen 13 16.626
Aedifica 2 834
Aegon 3.257 320.339
AFC Ajax 537 7.027
Affimed NV 2 5.779
ageas 5.843 109.785
Agfa-Gevaert 13 1.897
Ahold 3.536 74.015
Air France - KLM 1.024 34.393
AIRBUS 1 2
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.778
Alfen 13 17.336
Allfunds Group 3 1.236
Almunda Professionals (vh Novisource) 651 4.247
Alpha Pro Tech 1 17
Alphabet Inc. 1 341
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.485 114.772
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.822 240.505
AMG 965 126.601
AMS 3 73
Amsterdam Commodities 303 6.527
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 384
Antonov 22.632 153.605
Aperam 91 14.202
Apollo Alternative Assets 1 17
Apple 5 322
Arcadis 251 8.628
Arcelor Mittal 2.024 318.771
Archos 1 1
Arcona Property Fund 1 272
arGEN-X 15 9.186
Aroundtown SA 1 186
Arrowhead Research 5 9.312
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.771
ASML 1.762 77.658
ASR Nederland 18 4.162
ATAI Life Sciences 1 7
Atenor Group 1 340
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.804
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.681

Beleggingsideeën van onze partners

Macro & Bedrijfsagenda

  1. 23 mei

    1. Samengestelde inkoopmanagersindex mei (Jap)
    2. Investeringen maart (NL)
    3. Consumentenvertrouwen mei (NL)
    4. Ackermans & Van Haaren Q1-cijfers
    5. Samengestelde inkoopmanagersindex mei (Dld)
    6. Ahold Delhaize - beleggersdag
    7. Samengestelde inkoopmanagersindex mei (eurozone)
    8. Samengestelde inkoopmanagersindex mei (VK)
    9. Aalberts - jaarvergadering
    10. Turkse centrale bank - rentebesluit
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda